IP Library Granted Patent US 8,397,721
Granted Patent B2
US 8,397,721 · App. 13/284,433 · Granted Mar 19, 2013

System and method of administering a pharmaceutical gas to a patient

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,397,721
App. No.
13/284,433
Granted
Mar 19, 2013
Kind
B2
Abstract

Methods and systems for delivering a total quantity of pharmaceutical gas to a patient. The methods and systems provide one of a low amount and high amount of pharmaceutical gas to a patient. The selection of the high amount or low amount may be determined by comparing the amount per unit of time of pharmaceutical gas delivered to the patient over the past number of breaths to the required quantity of pharmaceutical gas per unit of time. Upon completion of delivering the total quantity of pharmaceutical gas to the patient, the system can terminate, continue, activate and alarm, etc.

Claims (29)

1. A system for administering to a patient a desired total quantity of pharmaceutical gas including at least one gas selected from CO and NO, the system comprising:

an inlet to connect to a source of pharmaceutical gas;

an outlet to connect to a device that introduces the pharmaceutical gas to the patient;

a setting control to determine a required quantity of pharmaceutical gas per unit of time to be delivered to the patient over a plurality of breaths; and

a gas control system to select one of a high amount and a low amount of pharmaceutical gas, the selection of the high amount or low amount being determined by comparing the amount of pharmaceutical gas per unit of time delivered to the patient over the past number of breaths to the required quantity of pharmaceutical gas per unit of time, the system configured to deliver the selected high amount or low amount of pharmaceutical gas to the patient.

2. The system of claim 1 , wherein the gas control system determines if the amount of pharmaceutical gas per unit of time is greater than the required quantity of pharmaceutical gas per unit of time then the low amount of pharmaceutical gas is selected and delivered to the patient on at least one subsequent breath and if the amount of pharmaceutical gas per unit of time is lower than the required quantity of pharmaceutical gas per unit of time then the high amount of pharmaceutical gas is selected and delivered to the patient on at least one subsequent breath.

3. The system of claim 2 , wherein the required quantity of pharmaceutical gas per unit of time to be delivered to the patient is greater than the low amount and less than the high amount.

4. The system of claim 3 , wherein comparing the amount of pharmaceutical gas per unit of time delivered to the patient over the past number of breaths to the required quantity of pharmaceutical gas per unit of time to be delivered is performed after every breath.

5. The system of claim 3 , wherein if the low amount is selected, the low amount is administered to the patient during subsequent breaths until the amount of pharmaceutical gas per unit of time delivered to the patient over the past number of breaths is less than the required quantity of pharmaceutical gas per unit of time to be delivered and then switching to the high amount for at least one subsequent breath.

6. The system of claim 3 , wherein if the high amount is selected, the high amount is administered to the patient during subsequent breaths until the amount of pharmaceutical gas per unit of time delivered to the patient over the past number of breaths is greater than the required quantity of pharmaceutical gas per unit of time to be delivered and then switching to the low amount for at least one subsequent breath.

7. The system of claim 3 , wherein the past number of breaths is all of the breaths beginning at onset of treatment.

8. The system of claim 2 , wherein the gas control system selects one of the high amount and low amount after every breath.

9. The system of claim 1 , wherein the system includes a breath trigger sensor to measure a current monitored respiratory breath rate.

10. The system of claim 1 , further comprising a second inlet to connect to a second gas source, the gas source being one of the high amount and low amount and the second gas source being the other of the high amount and low amount.

11. The system of claim 1 , further comprising an alarm.

12. The system of claim 11 , wherein the system activates the alarm when the desired total quantity of pharmaceutical gas has been delivered to the patient.

13. A method of delivering to a patient a desired total quantity of a pharmaceutical gas including at least one of CO and NO, the method comprising:

determining a required quantity of pharmaceutical gas per unit of time to be delivered to the patient;

administering an amount of the pharmaceutical gas to the patient during inspiration over at least one breath;

determining the amount of pharmaceutical gas per unit of time delivered to the patient over a past number of breaths;

selecting one of a high amount of pharmaceutical gas and a low amount of pharmaceutical gas to be delivered to the patient on a subsequent breath by comparing the amount of pharmaceutical gas per unit of time delivered to the patient over the past number of breaths to the required quantity of pharmaceutical gas per unit of time to be delivered to the patient, and selecting either the high amount of pharmaceutical gas or the low amount of pharmaceutical gas to be delivered on a subsequent breath; and

delivering either the high amount or the low amount of pharmaceutical gas to the patient on at least one subsequent breath.

14. The method of claim 13 , wherein if the amount of pharmaceutical gas per unit of time is greater than the required quantity of pharmaceutical gas per unit of time then the low amount of pharmaceutical gas is selected and if the amount of pharmaceutical gas per unit of time is lower than the required quantity of pharmaceutical gas per unit of time then the high amount of pharmaceutical gas is selected.

15. The method of claim 14 , wherein the required quantity of pharmaceutical gas per unit of time to be delivered to the patient is greater than the low amount and less than the high amount.

16. The method of claim 15 , wherein comparing the amount of pharmaceutical gas per unit of time delivered to the patient over the past number of breaths to the required quantity of pharmaceutical gas per unit of time to be delivered is performed after every breath.

17. The method of claim 16 , wherein if the low amount is selected, the low amount is administered to the patient during subsequent breaths until the amount of pharmaceutical gas per unit of time delivered to the patient over the past number of breaths is less than the required quantity of pharmaceutical gas per unit of time to be delivered and then switching to the high amount for at least one subsequent breath.

18. The method of claim 16 , wherein if the high amount is selected, the high amount is administered to the patient during subsequent breaths until the amount of pharmaceutical gas per unit of time delivered to the patient over the past number of breaths is greater than the required quantity of pharmaceutical gas per unit of time to be delivered and then switching to the low amount for at least one subsequent breath.

19. The method of claim 16 , wherein the past number of breaths is all of the breaths beginning at onset of treatment.

20. The method of claim 13 , wherein the pharmaceutical gas is delivered to the patient's alveoli during a first half on an inspiratory cycle.

Assignments (13)
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0454 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0035 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jul 22, 2019
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 049822/0674 →